Wechalekar, Ashutosh D <br/><br/>
Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis.  [electronic resource] 

 -  Blood  Jan 2007 
 - 457-64 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0006-4971 
<br/><br/><label>Standard No.: </label>10.1182/blood-2006-07-035352  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Amyloidosis--diagnosis<br/>Cyclophosphamide--administration & dosage<br/>Dexamethasone--administration & dosage<br/>Disease Progression<br/>Dose-Response Relationship, Drug<br/>Drug Therapy, Combination<br/>Drug-Related Side Effects and Adverse Reactions<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Immunoglobulin Light Chains--immunology<br/>Male<br/>Middle Aged<br/>Predictive Value of Tests<br/>Prospective Studies<br/>Risk Factors<br/>Survival Rate<br/>Thalidomide--administration & dosage<br/>Treatment Outcome